Protocol Ledger

NCT05327114 · Phase II/III · RECRUITING

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Interventional Phase II/III clinical trial protocol NCT05327114 sponsored by Johnson & Johnson / Janssen in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-23 Enrollment: 201 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05327114
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)201 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05327114
Protocol FieldVerified Registry Value
NCT IdentifierNCT05327114
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment201 participants (ESTIMATED)
Registered Start Date2022-09-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05327114
Hospital Research SiteLocationSite Profile
Augusta UniversityAugusta, GAOpen Hospital Dossier ->
University of Kansas Medical CenterKansas City, KSOpen Hospital Dossier ->
Johns Hopkins Hospital and Kimmel Cancer CenterBaltimore, MDOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI